Compare NUVB & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVB | WVE |
|---|---|---|
| Founded | 2018 | 2012 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | N/A | 2015 |
| Metric | NUVB | WVE |
|---|---|---|
| Price | $6.01 | $13.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 16 |
| Target Price | $10.44 | ★ $29.94 |
| AVG Volume (30 Days) | ★ 6.3M | 4.1M |
| Earning Date | 03-05-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $26,748,000.00 | ★ $109,230,000.00 |
| Revenue This Year | $616.63 | N/A |
| Revenue Next Year | $202.59 | $16.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1137.19 | 103.75 |
| 52 Week Low | $1.54 | $5.28 |
| 52 Week High | $9.75 | $21.73 |
| Indicator | NUVB | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 29.46 | 45.52 |
| Support Level | $6.07 | $13.72 |
| Resistance Level | $6.63 | $15.97 |
| Average True Range (ATR) | 0.53 | 1.34 |
| MACD | -0.39 | -0.50 |
| Stochastic Oscillator | 11.03 | 9.08 |
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.